Jeffrey Millman, Ph.D., authored a review article published this month in the American Diabetes Association (ADA) journal Diabetes entitled “Autologous Pluripotent Stem Cell-Derived β-Like Cells for Diabetes Cellular Therapy”. This article discusses the state-of-the-art in stem cell technology for treating diabetes by replacing dead or dysfunctional insulin-producing β cells with cells manufactured in the laboratory. Included his discusses the major advances made in recent years along with the remaining major challenges that still face this approach. It is the hope of Dr. Millman and other researchers, including co-author Felicia Pagliuca, Ph.D., VP of Cell Biology Research and Development at Semma Therapeutics, that transplantation of these cells can alleviate symptoms of diabetes and replace the need for insulin injections.
Dr. Jeffrey Millman is a faculty member in the Departments of Medicine and Biomedical Engineering and focuses his research on the development of improved bioengineering and stem cell technologies to develop a cellular therapy product for diabetes. His scientific contributions were recently recognized by the JDRF with a Career Development Award.